Safety of bevacizumab in patients younger than 4 years of age

Clinical and Translational Oncology

Volumn 18, Issue 5, 2016, Pages 464-468

  Millan, N C ^a   Poveda, M J ^a   Cruz, O ^a   Mora, J ^a  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Antiangiogenesis; Bevacizumab; Infant and toddlers; Infant tumors

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMATINIB; IRINOTECAN; TEMOZOLOMIDE; TOPOTECAN; VINBLASTINE; VINCRISTINE; ANGIOGENESIS INHIBITOR;

ANEMIA; ARTICLE; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CLINICAL ARTICLE; CONGENITAL BLOOD VESSEL MALFORMATION; DRUG EFFICACY; DRUG SAFETY; EWING SARCOMA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; MALE; NEPHROBLASTOMA; NEUROBLASTOMA; PANCYTOPENIA; PATHOLOGIC FRACTURE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR TUMOR; WOUND DEHISCENCE; ADOLESCENT; ADULT; CANCER STAGING; FOLLOW UP; MIDDLE AGED; NEOPLASMS; PATHOLOGY; PROGNOSIS; SAFETY; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SAFETY; SURVIVAL RATE; YOUNG ADULT;

EID: 84941348641     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1389-5     Document Type: Article

References (17)

1. Glade Bender J, Yamashiro DJ, Fox E. Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. Oncologist. 2011;16:1614–25.
2. Greenberger S, Bischoff J. Infantile hemangioma—mechanism(s) of drug action on a vascular tumor. Cold Spring Harb Perspect Med. 2011;1:a006460.
3. Megison ML, Gillroy LA, Beierle EA. Cell survival signaling in neuroblastoma. Anticancer Agents Med Chem. 2013;13:563–75.
4. Schiavetti A, Ingrosso A, Antenucci A, Federici T, Megaro G, De Luca L, et al. Circulating vascular endothelial growth factor in childhood solid tumors: plasma and serum measurements. Anticancer Res. 2012;32:3565–9.
5. Hintsala E, Bono P, Andersson S, Kivivuori SM. Quantification of plasma and bone marrow VEGF and angiopoietin-2 levels in pediatric malignancies. J Pediatr Hematol Oncol. 2012;34:503–10.
6. Berendsen AD, Olsen BR. How vascular endothelial growth factor-A (VEGF) regulates differentiation of mesenchymal stem cells. J Histochem Cytochem. 2014;62:103–8.
7. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, et al. VEGF is required for growth and survival in neonatal mice. Development. 1999;126:1149–59.
8. Aguilera D, Mazewski C, Fangusaro J, MacDonald TJ, McNall-Knapp RY, Hayes LL, et al. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Childs Nerv Syst. 2013;29:589–96.
9. de Pasquale MD, Castellano A, de Sio L, de Laurentis C, Mastronuzzi A, Serra A, et al. Bevacizumab in pediatric patients: how safe is it? Anticancer Res. 2011;31:3953–7.
10. Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg. 2012;116(2):341–5.
11. Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, et al. Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res 2013;19:236–246. Erratum in: Clin Cancer Res. 2013;19:1914.
12. Hsu CH, Lober RM, Li MD, Partap S, Murphy PA, Barnes PD, Fisher PG, Yeom KW. Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab. J Neurooncol. 2015;122(3):491–6.
13. Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas—a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2014;16(2):310–7.
14. Avery RA, Hwang EI, Jakacki RI, Packer RJ. Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. JAMA Ophthalmol. 2014;132(1):111–4.
15. Venkatramani R, Malogolowkin MH, Mascarenhas L. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. Pediatr Blood Cancer. 2014;61(4):756–9.
16. Conde N, Cruz O, Albert A, Mora J. Antiangiogenic treatment as a pre-operative management of alveolar soft-part sarcoma. Pediatr Blood Cancer. 2011;57(6):1071–3.
17. Voss SD, Glade-Bender J, Spunt SL, DuBois SG, Widemann BC, Park JR, et al. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children’s Oncology Group Phase I Consortium. Pediatr Blood Cancer. 2015;62(1):45–51.